BioStem Technologies Q2 2024 Earnings Report $14.44 -0.98 (-6.36%) (As of 12/20/2024 05:55 PM ET) Earnings History BioStem Technologies EPS ResultsActual EPS$0.30Consensus EPS $0.12Beat/MissBeat by +$0.18One Year Ago EPSN/ABioStem Technologies Revenue ResultsActual Revenue$74.49 millionExpected Revenue$43.99 millionBeat/MissBeat by +$30.50 millionYoY Revenue GrowthN/ABioStem Technologies Announcement DetailsQuarterQ2 2024Date8/12/2024TimeTASConference Call ResourcesConference CallBSEM Earnings History Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. BioStem Technologies Earnings HeadlinesKane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound GelNovember 27, 2024 | globenewswire.comBioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental AllograftsNovember 25, 2024 | globenewswire.comRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years. December 22, 2024 | Stansberry Research (Ad)BioStem Technologies, Inc.: BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare GlobalNovember 21, 2024 | finanznachrichten.deBioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare GlobalNovember 20, 2024 | globenewswire.comBSEM: Medicare Issues Shouldn’t Impact BioStemNovember 15, 2024 | finance.yahoo.comSee More BioStem Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioStem Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioStem Technologies and other key companies, straight to your email. Email Address About BioStem TechnologiesBioStem Technologies (OTCMKTS:BSEM), a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.View BioStem Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
